STEM CELLS UNLOCKED

Syntax Bio is a preclinical-stage biotech company overcoming the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.

TECHNOLOGY

Our Cellgorithm technology provides control over the complex developmental biology needed to manufacture stem cell-derived cell therapies. 

The Syntax platform provides customizable, epigenetic​ instructions to program step-wise cellular differentiation processes

INVESTORS

TEAM

LEADERSHIP TEAM

Brad Merrill, PhD
Cofounder, Head of Innovation

Niko Balanis, PhD
Cofounder, VP Data Sci & Molecular Bio

Nick Timmins, PhD
CSO

Ryan Clarke, PhD
Cofounder, CTO

John Flavin, MBA
CEO

BOARD OF DIRECTORS

John Flavin, MBA

Ryan Clarke, PhD

Andy May, DPhil
Executive Chairman; Entrepreneur in Residence, DCVC Bio

Satoshi Konagai, MS, MBA
Investment Lead, Astellas Venture Management

ADVISORS

Matt MacDougall, MD, PhD
Scientific Cofounder, Immunology Physician, Stanford University

Alex Chavez, MD, PhD
Associate Professor, UCSD

Ryan Larson, PhD
Head of Translation, Umoja Biopharma

Ryan Crisman, PhD
Cofounder, CTO Umoja Biopharma


PRESS

September 18, 2024

September 17, 2024

September 17, 2024

September 24, 2023

JANUARY 21, 2021

CONTACT

JOIN US ON OUR
JOURNEY TO reinvent
THE cellular differentiation process